81918-96-9

Usage

Uses

Used in Pharmaceutical Industry:
14,15-Leukotriene A4 is used as a pharmaceutical intermediate for the synthesis of other biologically active leukotrienes, which have potential applications in the treatment of various diseases, including asthma and inflammatory disorders.
Used in Research Applications:
14,15-Leukotriene A4 is used as a research tool in the study of leukotriene biosynthesis, signaling pathways, and their role in disease pathogenesis. It helps researchers understand the mechanisms of action and develop targeted therapies for related conditions.

InChI:InChI=1/C20H30O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-10,13,16,18-19H,2-3,5,11-12,14-15,17H2,1H3,(H,21,22)/b6-4-,9-7-,10-8+,16-13+/t18-,19-/m1/s1

Upstream product

• 73890-63-8 15(S)-hydroperoxy-5,8,11,13-eicosatetratetraenoic acid 
• 2566-89-4 methyl arachidonate 
• 89408-78-6 (Z)-(2R,3S)-1-(tert-Butyl-diphenyl-silanyloxy)-oct-5-ene-2,3-diol 
• 89408-79-7 (2R,3S)-1-(tert-Butyl-diphenyl-silanyloxy)-octane-2,3-diol 
• 89408-82-2 (6S,7S)-epoxy-(2E,4E)-dodecadienal 
• 89461-52-9 (2R,3S)-2,3-epoxyoctanal 
• 82709-37-3 1,1,1-trimethoxy-5-hexyne 
• 88557-30-6 (2R,3S)-octane-1,2,3-triol 
• 89408-83-3 ((Z)-7-Carboxy-hept-3-enyl)-triphenyl-phosphonium; iodide 
• 89461-53-0 trans-4,5-epoxy-(E)-2-decenal 
• 452-51-7 D-2-deoxyribose 
• 75290-58-3 (14S,15S)-leukotriene A₄ methyl ester 
• 89461-51-8 [(2S,3S)-3-pentyloxiran-2-yl]methanol 

Relevant academic research and scientific papers

Biosynthesis, isolation, and NMR analysis of leukotriene A epoxides: Substrate chirality as a determinant of the cis or trans epoxide confi guration

Leukotriene (LT)A 4 and closely related allylic epoxides are pivotal intermediates in lipoxygenase (LOX) pathways to bioactive lipid mediators that include the leukotrienes, lipoxins, eoxins, resolvins, and protectins. Although the structure and stereochemistry of the 5-LOX product LTA 4 is established through comparison to synthetic standards, this is the exception, and none of these highly unstable epoxides has been analyzed in detail from enzymatic synthesis. Understanding of the mechanistic basis of the cis or trans epoxide confi guration is also limited. To address these issues, we developed methods involving biphasic reaction conditions for the LOX-catalyzed synthesis of LTA epoxides in quantities suffi cient for NMR analysis. As proof of concept, human 15-LOX-1 was shown to convert 15 S-hydroperoxy-eicosatetraenoic acid (15 S-HPETE) to the LTA analog 14 S ,15 S-trans-epoxy-eicosa-5 Z ,8 Z ,10 E ,12 E-tetraenoate, confi rming the proposed structure of eoxin A 4 . Using this methodology we then showed that recombinant Arabidopsis AtLOX1, an arachidonate 5-LOX, converts 5 S-HPETE to the trans epoxide LTA 4 and converts 5 R-HPETE to the cis epoxide 5-epi-LTA 4 , establishing substrate chirality as a determinant of the cis or trans epoxide confi guration. The results are reconciled with a mechanism based on a dual role of the LOX nonheme iron in LTA epoxide biosynthesis, providing a rational basis for understanding the stereochemistry of LTA epoxide intermediates in LOX-catalyzed transformations.Copyright

THE STEREOSPECIFIC SYNTHESIS OF 14S,15S-OXIDO 5Z,8Z,10E,12E-EICOSATETRAENOIC ACID

The first total and stereospecific synthesis of 14S,15S-oxido 5Z,8Z,10E,12E-eicosatetraenoic acid from 2-deoxy-D-ribose has been achieved.